Simulations Plus, Inc. (NASDAQ: SLP) Starts Presentation at LD Micro Main Event
Simulations Plus (NASDAQ: SLP) develops drug discovery and development software and provides preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models related to drug-induced liver injury and nonalcoholic fatty liver disease. SLP’s software is licensed to use in drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. The company’s integration of science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into its software has made the company a recognized software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit the company’s website at www.Simulations-Plus.com.…